Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dilution always hurts , Temporarily…unless they blow the $$$ on their own salaries! So now their balance sheet is stronger, meaning runway prob until mid-2024…picked up a bunch in the $6’s, shooting for $8-9 soon as Mr. Market settles..
This ticker is never easy to understand price movement and Valuation but I adding anyway! Someday a takeout in the 30’s (~$3b cap)..
Shorties chasing
To cover!
None of really know the reason(s) but it would be encouraging if we had some Insider buys again..until then, I continue to write naked Apr. 20 puts( took in $3 yesterday) .. $17 if Put not a bad price
Coming from personal experience, after FDA approval and launch, I did my first Cologuard sample, came back negative.. fast forward to June 22’, it picked up DNA stool issues and had colonoscopy in November..10 polyps removed( not cancer) but doc has concerns and doing 2 Colonoscopy 1 Yr. from now!
Highly recommend to all to try both procedures, both may save your life!!
Unfortunately a Current owner in the low $3’s and was bidding .$34 pre announcement to average down seeing they had/have ~$50mm cash( 74m shares out(~$.60cv)..of course they’ll have cash burn prior to liquidation but need to do deep dive to see if they have other valuable assets to offset burn..
My friends @ Maxim, Dawson J, EFHutton have private’s waiting for SEC comments to IPO, but RM/Spac is the only option today it seems..blows my mind that MGMT/Bankers couldn’t find candidates:
"The Board of Directors and management, together with its external advisors, devoted substantial time and effort in identifying and pursuing opportunities to enhance shareholder value; however, that process did not yield a potential transaction which the Board viewed as reasonably likely to provide greater realizable value to its shareholders than the complete dissolution and liquidation of the Company."
Another one bites the dust!
Can’t believe their bankers couldn’t find a RM candidate!
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
DD, saw that and at 1st was scratching my head, lol .. good news though, thx for update
Can’t do 25’s yet, need to lower cost 1st..I’m all over the place with couple accounts… anywhere from ~$13-high 20’s:
DATE ACQUIRED
QUANTITY
COST BASIS
ACQUIRED 11/18/2022
3000 Shares at $22.77/Share
Unrealized Gain/Loss: -$2080.42 (-3.05%)
ACQUIRED 09/12/2022
300 Shares at $26.50/Share
Unrealized Gain/Loss: -$1326.00 (-16.68%)
ACQUIRED 09/12/2022
200 Shares at $26.49/Share
Unrealized Gain/ Loss: -$882.00 (-16.65%)
ACQUIRED 05/13/2022
400 Shares at $13.83/Share
Unrealized Gain/ Loss: +$3300.00 (+59.65%)
ACQUIRED 02/16/2022
100 Shares at $13.15/Share
Unrealized Gain/Loss: +$893.00 (+67.91%)
And IRA
RVNC +4000 k
$22.08 average
Agreed , that’s why April20’s the strike.. if Put , then ~$17.10 , if not then $8700 premium can buy some nice Xmas gifts for the Fam :)
Seems the best way to play this ticker is by selling Puts! Minimal Revs until Q1-2023 are reported.. hence, offering out Apr. 20’s @ 2.90 decent IV , Greeks
Thanks Dew, appreciated!
Perhaps the Mkt. Cap (~$40mm) discourages many…started a small position and seems they are good stewards of Cash ( as Blade suggested)
Btw, Always appreciate your opinion on R*VNC.
Is anybody going to this event? Or at least follow this Bio? Thanks in advance!
Details of the poster presentation are as follows:
Title: Phase 1a/b Safety Study of Intravesical
Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1)
Poster Number: 191
Poster Category: Bladder 4 (Bladder Cancer
> Non-Muscle Invasive Bladder Cancer)
Session Title: E-Poster Displays
Session Date and Time: Friday, December 2
at 9:00 a.m. - 10:00 a.m.
Location: Sapphire ABEFIJMN, Hilton San
Diego Bayfront, San Diego, California
ADVANCED-1 is a Phase 1 dose-finding, open-label trial (NCT05085977 and NCT05085990)
evaluating TARA-002 in treatment-naive and
treatment-experienced NMIBC patients with high-grade carcinoma in situ (CIS) and high-grade papillary tumors (Ta). In the initial dose escalation phase of the trial, patients will
receive six weekly intravesical doses of TARA-
002. The primary objective of the trial is to
Had to sit at .32,
Got filled in some there , still
~50k left if anybody wants out!!
True that , but got some at least.. will stay on bid @ .30 til / if filled..
Actually made $666 so far , lmao :)
Most Recent Value
$6,381.75
(19,050.000 Shares)
+$666.75 (+11.67%)
Gave me partial this a.m: lol
Partially Filled
Buy 100,000 Shares of
TLOFF Limit at $0.30
(Good 'til Canceled)
$5,715.00
Status
Partially Filled
Symbol
TLOFF
Hmmm, I have a 100k bid @ .30 and today shows low of .29 but didn’t get hit.. pinky land stinks!!
New to this play, so is management capable of building out operations? Anybody dig deep with DL on them? I ask because in the past, I had a bad experience with mgmt being inept with locals concerns with acid runoff, other pollutants and environmentalist stoping the project…thx in advance
Later today:
company will participate in the Stifel 2022 Healthcare Conference, taking place November 15-16, 2022, in New York City. Chief Financial Officer, Tobin Schilke, is scheduled to present on Tuesday, November 15, at 3:00 p.m. ET.
Interested parties can access the live audio webcast for this conference from the Events page of the Investor Relations section of the company's website at www.revance.com.
Lots of action today,
Hmmm
Anybody picking up shares down here? $120’s ?
Started a small starter position this a.m
Voted for Rosen slate of BOD!
Shorties probably realize not much info will be disclosed on -Nov 7th Eps / Conf. Call ( unless Foley surprises with FDA acceptance of sBLA ; although prob too soon for that)..perhaps Dew D can remind us what typical response time is?
Selling the Nov. 25puts ( and now the $22.5’s appealing) may be the way to go- decent premiums :)
The G.O.A.T played like a jackazz today, hopefully management can do better! He needs to ask the wife to reconsider taking him back, lol
I’ll talk to the Big guy and let you know what he says! G.O.A.T
Go Bucs :)
RW, join me on the ‘ask’ @ $2.5 Nov 25’s ( if ‘Put’ before expiration) not bad of a cost $22.5…otherwise ~$2500 profit 10p/30day wait..lol
Because there seems to be downward pressure, irrespective of XBI(etc.-other indices ),Revance Hasn’t been acting ‘normal’..
so I’m playing it thru selling Nov. 25 puts( prob will ‘sell to open’) addtl if they get to $3+
If exercised, My is Cost is $22.5 on avg ( started on Monday @ $1.75 per put)
Very w’com , and finally got filled @ $1.75 ( Nov. 25 strike)…someone doing calendar spread (200/400 on put side, interesting)
Em, dropped my offer to $1.85 on this piece, good read bud!
Volume and O/I picking up last couple days, something brewing ( just can’t tell if Longs or Shorts, hmm)?
Pick up small lot low 25’s, but also offering Nov. 25’s (puts)and collecting between 1.75-1.85….have another batch @ 1.90 ask if she can pull back , might get hit :)…implied vol @65%
GL brother ;)
Hear that, same but kept some and rebuilt especially when it got heated recently.. Point72( Cohen affiliated) and Rubric (Rosen) are players so had to participate..valuation cheap relative to what these 2 can do if Bio’s can rally in a better market..($4-5 at least 1/2B cap)
This is at least a 1st good start:
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
https://ih.advfn.com/p.php?pid=nmona&article=89202436
Gotta love Rubrics’ efforts :)
Rosen’s gonna need a bigger boat’load( 14% not going to cut it)
This is another reason why I doubt B/out:
‘Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year’
But we are just guessing, however Takeout would be prob be in early teens , not 20’s my assumption ( $1b+ mkt cap minimum anyway)
This is another reason why I doubt B/out:
‘Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year’.
But we are just guessing, however Takeout would be prob be in early teens , not 20’s my assumption ( $1b+ mkt cap minimum anyway)
Hope you’re right, but I doubt management/bod wants to let go until at least 2nd half 23’ ( file bla in Q1, Pdufa date July’ish 23)..c-ste turnover could mean many things, but we shall see.
GLTA
Grats! FYI- Rjames upgraded to $10 target ..maybe Mizhu as well.. just need Goldman slacks to move target higher than $3, lol
When ~$220mm hits the balance sheet, and ATM is near completion( started at $75m, but took ~10mm in), then she runs in anticipation of Sickle Cell update...
I’ll be in the CC w/ my meezly 10k shares .. think it’s all about the 3rd drug in Q1 that moves the needle, but 2/2 ain’t bad! Just glad Kevin Tang has built a position, he’s pretty bright, successful Biotech investor!